A Phase 1, First-in-human, Randomized, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose Study in Healthy Adults and Open-label Single Dose Study in Patients With Alzheimer's Disease to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VG-3927
Latest Information Update: 11 Feb 2025
At a glance
- Drugs VG 3927 (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions; First in man
- Sponsors Vigil Neuroscience
Most Recent Events
- 30 Jan 2025 Status changed from recruiting to completed.
- 19 Sep 2024 Planned number of patients changed from 90 to 108.
- 12 Sep 2024 Addition of open label single dose study in patients with Alzheimer's disease, change in the number of treatment arms from 2 to 3, and change in planned patient number from 90 to 108.